Drug Profile
Cannabidiol inhalation - Rapid Therapeutic Science Laboratories
Alternative Names: Cannabidiol MDI - Rapid Therapeutic Science Laboratories; CBD Metered Dose Inhaler - Rapid Therapeutic Science LaboratoriesLatest Information Update: 04 Aug 2022
Price :
$50
*
At a glance
- Originator Rapid Therapeutic Science
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Antioxidants; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Anxiety disorders; Attention-deficit hyperactivity disorder; Depressive disorders; Insomnia; Pain
Most Recent Events
- 28 Jul 2022 Rapid Therapeutic Science Laboratories announces intention to submit IND to US FDA for Depressive disorder, Anxiety disorder, Insomnia, Attention-deficit hyperactivity disorder and Pain in Q3 of 2022
- 22 Jul 2022 Rapid Therapeutic Science plans a phase I trial for Depressive disorder, Anxiety disorder, Insomnia, Attention-deficit hyperactivity disorder and Pain in USA
- 02 Jun 2021 Rapid Therapeutic Science Laboratories plans phase I trials in Depressive disorder, Anxiety disorder, Insomnia, Attention-deficit hyperactivity disorder and Pain in USA (Inhalation)